Gland Pharma

Gland PharmaGLAND.NS

Price

$ 21.9092

Market Capitalization

$ 3.61 B

Shares Outstading

164.752 M

Change

$ -0.17

Percentage Change

-0.78 %

Country

India 🇮🇳

Industry

Drug Manufacturers—General

Healthcare

Exchange

National Stock Exchange of India

IPO

2020-11-20

Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products un

PE Ratio of Gland Pharma ( GLAND.NS)

PE Ratio : 41.2183

Gland Pharma has PE Ratio of 41.2183 .The current price of Gland Pharma is $21.9092 (-0.78 %).

The Price-to-Earnings (P/E) ratio is a financial metric that compares a company's current stock price to its earnings per share (EPS). It provides insight into the market's expectations regarding a company's future earnings growth and overall valuation, with a higher P/E suggesting greater growth expectations or optimism.
PE Ratio of Gland Pharma from 2020 to 2024
Year on Year PE Ratio of Gland Pharma
PE Ratio
YearPE RatioChange %
31-03-202326.739-39.7%
31-03-202244.3459.84%
31-03-202140.371-1.01%
31-12-202040.784
Market Cap of Magnificent 7

Stock Ticker

Market Cap

Price

Change

Price(30 Days)

Country

$ 3.335 T

$ 135.58

0.00%

$ 0

United States🇺🇸

$ 3.317 T

$ 446.34

0.00%

$ 0

United States🇺🇸

$ 3.286 T

$ 214.29

0.00%

$ 0

United States🇺🇸

$ 2.171 T

$ 176.45

0.00%

$ 0

United States🇺🇸

$ 1.902 T

$ 182.81

0.00%

$ 0

United States🇺🇸

$ 1.787 T

$ 7.38371

0.01%

$ 0

Saudi Arabia🇸🇦

$ 1.267 T

$ 499.49

0.00%

$ 0

United States🇺🇸

NEWSLETTER

MarketStreak weekly Newsletter

Get weekly Stock Market/Crypto News and Jobs updates directly to your inbox.

MarketStreak Research

Research

Latest data-backed business trends, research insights, and industry analyses.

MarketStreak Inc.

TEXAS, USA 🇺🇸

Disclaimer : The content on our website, including hyperlinked sites, associated applications, forums, blogs, and social media accounts, is for general information only and sourced from third-party providers. We offer no warranties regarding the content's accuracy or updatedness. Please note that our content should not be considered financial or legal advice. Always conduct thorough research and consult with a financial advisor before making any decisions. Trading is a high-risk activity that can lead to significant losses, so please seek professional guidance before making any trading decisions. Our content is not meant to be a solicitation or offer.